Tricyclic antidepressants and fibromyalgia: what is the mechanism of action?

LAWSON, Kim (2002). Tricyclic antidepressants and fibromyalgia: what is the mechanism of action? Expert opinion on investigational drugs, 11 (10), 1437-1445.

Full text not available from this repository.
Link to published version:: https://doi.org/10.1517/13543784.11.10.1437
Related URLs:

    Abstract

    Fibromyalgia is a chronic pain disorder of which other clinical features, such as persistent fatigue and disordered sleep, may be a secondary consequence. The initial pharmacological approach to treating the disorder is the management of the pain. Tricyclic antidepressants are the most effective drugs in use so far, especially when administered in combination with other therapies (e.g., selective serotonin re-uptake inhibitors), which suggests modulation of the neurotransmitters serotonin and noradrenaline. The effectiveness of amitriptyline and related tricyclic antidepressants, however, is consistent with the involvement of mechanisms, such as potassium channel modulation and NMDA receptor antagonism, in addition to or in place of the modulation of monoamine neurotransmitters. Investigation of the importance of each of the pharmacological properties of amitriptyline and related molecules in the management of fibromyalgia could provide clues for the rational design of new drugs.

    Item Type: Article
    Research Institute, Centre or Group - Does NOT include content added after October 2018: Biomolecular Sciences Research Centre
    Identification Number: https://doi.org/10.1517/13543784.11.10.1437
    Page Range: 1437-1445
    Depositing User: Jamie Young
    Date Deposited: 28 May 2015 11:38
    Last Modified: 18 Mar 2021 18:46
    URI: http://shura.shu.ac.uk/id/eprint/9913

    Actions (login required)

    View Item View Item

    Downloads

    Downloads per month over past year

    View more statistics